LEVODOPA-CARBIDOPA 25 MG
CARBIDOPA : 25 MG LEVODOPA : 250 MG · DIN 02182858 · APOTEX INC
Health Canada status: APPROVED
What is LEVODOPA-CARBIDOPA?
LEVODOPA-CARBIDOPA 25 MG contains CARBIDOPA : 25 MG LEVODOPA : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02182858, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 30-May-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is LEVODOPA-CARBIDOPA called?
The same molecule, LEVODOPA AND DECARBOXYLASE INHIBITOR, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Stalevo® | Latin | Sweden |
| Stalevo | Latin | Bahrain, Brazil, Czechia, Norway |
| Levodopa/Carbidopa/Entacapone Orion | Latin | Sweden |
| Carlevent | Latin | Australia |
| L.C.E. Sandoz | Latin | Australia |
| Lecteva | Latin | Australia |
| Sastravi | Latin | Sweden |
| Madopar | Latin | Australia, Czechia, Sweden |
| Duodopa | Latin | Australia, Bahrain, Czechia, Norway |
| Levodopa/Carbidopa/Entacapone G.L. Pharma | Latin | Sweden |
| Levodopa/Carbidopa/Entacapone Holsten | Latin | Sweden |
| PROLOPA | Latin | Brazil |
| EKSON | Latin | Brazil |
| APO-Levodopa/Carbidopa | Latin | Australia |
| CORBILTA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02182858 |
|---|---|
| Brand name | LEVODOPA-CARBIDOPA |
| Generic / active ingredient | CARBIDOPA : 25 MG LEVODOPA : 250 MG |
| Manufacturer | APOTEX INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 30-May-2024 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02182858 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2182858 |
| Brand name | LEVODOPA-CARBIDOPA |
| Active ingredient / INN | CARBIDOPA : 25 MG LEVODOPA : 250 MG |
| ATC code | N04BA02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
Which pack is which?
| Strength on the label | 25 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR. 23 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-LEVOCARB CR | 200 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02245211 |
| AA-LEVOCARB CR | 25 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02272873 |
| AG-LEVOCARB | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02551365 |
| APO-LEVOCARB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02195933 |
| APO-LEVOCARB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02195941 |
| APO-LEVOCARB | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02195968 |
| AURO-LEVOCARB | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02531593 |
| AURO-LEVOCARB | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02531615 |
| AURO-LEVOCARB | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02531607 |
| DUODOPA | 5 MG | GEL | ABBVIE CORPORATION | MARKETED | DIN 02292165 |
Who else supplies LEVODOPA AND DECARBOXYLASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVODOPA AND DECARBOXYLASE INHIBITOR appears in 108 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LEVODOPA AND DECARBOXYLASE INHIBITOR cost around the world?
LEVODOPA AND DECARBOXYLASE INHIBITOR is listed on 15 national price registers Nexara tracks, across 449 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Sweden | AIP (pharmacy purchase price) | 16 | 100 | 03 Sep 2026 |
| Australia | ex-manufacturer | 24 | 88 | 08 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 34 | 57 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 32 | 38 | 03 Sep 2026 |
| Spain | PVP con IVA (public price) | 27 | 27 | 05 Sep 2026 |
| Belgium | public | 26 | 26 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 12 | 26 | 03 Sep 2026 |
| Brazil | preco fabrica (ex-factory ceiling) | 10 | 23 | 02 Sep 2026 |
| United Kingdom | hospital | 14 | 14 | 31 Aug 2026 |
| Luxembourg | reimbursement | 13 | 13 | 05 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 5 | 13 | 07 Sep 2026 |
| Slovakia | categorised final price | 12 | 12 | 02 Sep 2026 |
| Bahrain | retail (max) | 3 | 6 | 01 Sep 2026 |
| Saudi Arabia | public | 5 | 5 | 01 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.